Management of Barrett Esophagus Following Radiofrequency Ablation
- PMID: 31391808
- PMCID: PMC6676349
Management of Barrett Esophagus Following Radiofrequency Ablation
Abstract
Radiofrequency ablation (RFA) effectively treats dysplastic Barrett esophagus (BE), reduces the risk of esophageal adenocarcinoma (EAC), and infrequently produces complications. Complications of RFA include chest discomfort, esophageal stricturing, and bleeding. However, chest discomfort is usually transient and mild, strictures are generally amenable to dilation, and clinically significant bleeding is rare. Following RFA, intestinal metaplasia recurs at a rate of approximately 10% per patient year of follow-up time. Postablation dysplastic BE and EAC are rare. Moreover, recurrent disease is generally responsive to further endoscopic therapy and is associated with a benign clinical course. Although RFA is effective at producing low rates of postablation EAC and dysplastic recurrence, data suggest that current consensus guidelines for postablation surveillance are overly aggressive, as they mirror those for treatment-naive cohorts. Future guidelines may attenuate surveillance intervals, reducing the burden of endoscopic surveillance while providing for adequate detection of recurrent disease. Additional studies are needed to determine the length of time patients should ultimately remain in surveillance programs. Uncertainty exists regarding the appropriate application of chemopreventive measures (including proton pump inhibitors, aspirin, and statins) and novel imaging and sampling modalities (such as optical coherence tomography and wide-area transepithelial sampling) to reduce the risk of recurrent disease and sampling error, respectively. These uncertainties represent targets for future investigations.
Keywords: Barrett esophagus; complications; durability; dysplasia; radiofrequency ablation.
Conflict of interest statement
Dr Shaheen receives research funding from Medtronic, CSA Medical, Interpace Diagnostics, and CDx Medical. Grant money from NIH Award K24DK100548 supported this research. Dr Reed has no relevant conflicts of interest to disclose.
Figures


Similar articles
-
Natural History of the Post-ablation Esophagus.Dig Dis Sci. 2018 Aug;63(8):2136-2145. doi: 10.1007/s10620-018-5066-8. Dig Dis Sci. 2018. PMID: 29671157 Review.
-
Late Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial.Gastroenterology. 2017 Sep;153(3):681-688.e2. doi: 10.1053/j.gastro.2017.05.044. Epub 2017 Jun 1. Gastroenterology. 2017. PMID: 28579538 Free PMC article. Clinical Trial.
-
Eliminating a need for esophagectomy: endoscopic treatment of Barrett esophagus with early esophageal neoplasia.Semin Thorac Cardiovasc Surg. 2014 Winter;26(4):274-84. doi: 10.1053/j.semtcvs.2014.12.004. Epub 2014 Dec 24. Semin Thorac Cardiovasc Surg. 2014. PMID: 25837538
-
Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus.Gastroenterology. 2018 Aug;155(2):316-326.e6. doi: 10.1053/j.gastro.2018.04.011. Epub 2018 Apr 13. Gastroenterology. 2018. PMID: 29655833 Free PMC article.
-
Durability of Endoscopic Treatment for Dysplastic Barrett's Esophagus.Curr Treat Options Gastroenterol. 2019 Jun;17(2):171-186. doi: 10.1007/s11938-019-00226-5. Curr Treat Options Gastroenterol. 2019. PMID: 31077058 Review.
Cited by
-
Comparative cost-effectiveness of three post-radiofrequency ablation surveillance intervals for Barrett's esophagus.Endosc Int Open. 2022 Aug 15;10(8):E1053-E1064. doi: 10.1055/a-1858-0945. eCollection 2022 Aug. Endosc Int Open. 2022. PMID: 35979029 Free PMC article.
-
A narrative review of Barrett's esophagus in 2020, molecular and clinical update.Ann Transl Med. 2020 Sep;8(17):1107. doi: 10.21037/atm-20-4406. Ann Transl Med. 2020. PMID: 33145326 Free PMC article. Review.
-
Eosinophilic esophagitis, Barrett's esophagus and esophageal neoplasms in the pediatric patient: a narrative review.Transl Gastroenterol Hepatol. 2021 Jul 25;6:32. doi: 10.21037/tgh-20-223. eCollection 2021. Transl Gastroenterol Hepatol. 2021. PMID: 34423153 Free PMC article. Review.
References
-
- Ronkainen J, Aro P, Storskrubb T et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129(6):1825–1831. - PubMed
-
- Zagari RM, Fuccio L, Wallander M-A et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57(10):1354–1359. - PubMed
-
- Johansson J, Håkansson H-O, Mellblom L et al. Prevalence of precancerous and other metaplasia in the distal oesophagus and gastro-oesophageal junction. ScandJ Gastroenterol. 2005;40(8):893–902. - PubMed
-
- Desai TK, Krishnan K, Samala N et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61(7):970–976. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources